Evidence map›Paper›PMID 40504630›Full record

ArticleJournal of medical Internet research2025

Digital Therapeutics for Cognitive Impairment: Exploring Innovations, Challenges, and Future Prospects.

Grace Yuange Zang, Keqin Rao, Jing Wu, Yunhan He, Yi Tang, Leiyu Shi

Abstract read
In one paragraph

Article in Journal of medical Internet research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Grace Yuange ZangDepartment of Health Policy and Management, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, United States.ORCID http://orcid.org/0009-0003-8851-7089
Keqin RaoInstitute for Hospital Management, Tsinghua University, Beijing, China.ORCID http://orcid.org/0009-0005-5652-9127
Jing WuNational Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center For Disease Control and Prevention, Beijing, China.ORCID http://orcid.org/0000-0003-3519-0839
Yunhan HeSchool of Psychology, Shenzhen University, Shenzhen, China.ORCID http://orcid.org/0000-0002-6241-882X
Yi TangDepartment of Neurology & Innovation Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University, National Center for Neurological Disorders, 45 Changchun Street, Beijing, 100053, China, 86 13811021432.ORCID http://orcid.org/0000-0002-8052-065X
Leiyu ShiDepartment of Health Policy and Management, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, United States.ORCID http://orcid.org/0000-0001-9227-0849

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Unlabelled: Recent advancements in cognitive neuroscience and digital technology have significantly accelerated the adoption of digital therapeutics for cognitive impairment. This viewpoint explores the innovative applications of digital therapeutics in the assessment, intervention, management, and monitoring of cognitive disorders while highlighting key challenges that impede their widespread integration into clinical practice. Drawing on the definition of cognitive digital therapeutics (CDTx) and the multistakeholder collaboration required for its development and implementation, this paper examines the role of digital technologies in cognitive health and explores challenges from multiple perspectives, including clinical practice, policy framework, user adoption, ethics and privacy, and data interoperability and system integration. In addition, this viewpoint offers strategic recommendations to address the challenges and future prospects of CDTx, emphasizing the importance of multistakeholder collaboration, prioritizing user-centered design, and leveraging emerging technologies such as artificial intelligence to enhance the scalability, sustainability, and future integration of CDTx.

Indexed as

Cognition DisordersCognitive DysfunctionDigital TechnologyArtificial IntelligenceHumansartificial intelligencecognitive digital therapeuticscognitive impairmentdigital therapeuticshealth technologyinnovative applicationsmultistakeholder collaboration

Identifiers

PMID40504630
PMCPMC12178222

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.